Second Sight Announces Publication of Positive Results in 3-Year FLORA Study of the Argus II
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. ("Second Sight" or "the Company") (Nasdaq:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful vision to blind patients, today announced the publication of a positive 3-year FLORA study in the Australian journal Clinical And Experimental Optometry for the Argus® II Retinal Prosthesis System ("Argus II"). The Functional Low-Vision Observer Rated Assessment (FLORA), a multi-part
